These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

295 related articles for article (PubMed ID: 34406358)

  • 1. Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Can Induce Acute Myopericarditis in Mouse Model.
    Li C; Chen Y; Zhao Y; Lung DC; Ye Z; Song W; Liu FF; Cai JP; Wong WM; Yip CC; Chan JF; To KK; Sridhar S; Hung IF; Chu H; Kok KH; Jin DY; Zhang AJ; Yuen KY
    Clin Infect Dis; 2022 Jun; 74(11):1933-1950. PubMed ID: 34406358
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myopericarditis after messenger RNA Coronavirus Disease 2019 Vaccination in Adolescents 12 to 18 Years of Age.
    Das BB; Kohli U; Ramachandran P; Nguyen HH; Greil G; Hussain T; Tandon A; Kane C; Avula S; Duru C; Hede S; Sharma K; Chowdhury D; Patel S; Mercer C; Chaudhuri NR; Patel B; Ang JY; Asmar B; Sanchez J; Khan D
    J Pediatr; 2021 Nov; 238():26-32.e1. PubMed ID: 34339728
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute Myopericarditis Post-Intravenous Injection of Coronavirus Disease 2019 (COVID-19) mRNA Vaccine Differs From Viral Myocarditis.
    Correa H; Soslow JH; Dendy JM; Creech CB
    Clin Infect Dis; 2022 Aug; 75(1):e926. PubMed ID: 34849644
    [No Abstract]   [Full Text] [Related]  

  • 4. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serological findings following the second and third SARS-CoV-2 vaccines in lung transplant recipients.
    Bárczi E; Varga V; Nagy A; Eszes N; Jáky-Kováts Z; Müller V; Bohács A
    Immun Inflamm Dis; 2022 Aug; 10(8):e646. PubMed ID: 35894705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tolerability of COVID-19 Infection and Messenger RNA Vaccination Among Patients With a History of Kawasaki Disease.
    Beckley M; Olson AK; Portman MA
    JAMA Netw Open; 2022 Aug; 5(8):e2226236. PubMed ID: 35960521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study.
    Husby A; Hansen JV; Fosbøl E; Thiesson EM; Madsen M; Thomsen RW; Sørensen HT; Andersen M; Wohlfahrt J; Gislason G; Torp-Pedersen C; Køber L; Hviid A
    BMJ; 2021 Dec; 375():e068665. PubMed ID: 34916207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucosal immunization with lactiplantibacillus plantarum-displaying recombinant SARS-CoV-2 epitopes on the surface induces humoral and mucosal immune responses in mice.
    Hwang IC; Valeriano VD; Song JH; Pereira M; Oh JK; Han K; Engstrand L; Kang DK
    Microb Cell Fact; 2023 May; 22(1):96. PubMed ID: 37161468
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
    Jalkanen P; Kolehmainen P; Haveri A; Huttunen M; Laine L; Österlund P; Tähtinen PA; Ivaska L; Maljanen S; Reinholm A; Belik M; Smura T; Häkkinen HK; Ortamo E; Kantele A; Julkunen I; Lempainen J; Kakkola L
    Microbiol Spectr; 2022 Apr; 10(2):e0225221. PubMed ID: 35262410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insights From a Murine Model of Coronavirus Disease 2019 (COVID-19) mRNA Vaccination-Induced Myopericarditis: Could Accidental Intravenous Vaccine Injection Induce Myopericarditis?
    Knowlton KU
    Clin Infect Dis; 2022 Jun; 74(11):1951-1952. PubMed ID: 34453510
    [No Abstract]   [Full Text] [Related]  

  • 12. Outbreak of SARS-CoV-2 B.1.617.2 (delta) variant in a nursing home 28 weeks after two doses of mRNA anti-COVID-19 vaccines: evidence of a waning immunity.
    Pierobon A; Zotto AD; Antico A; De Antoni ME; Vianello L; Gennari M; Di Caprio A; Russo F; Brambilla G; Saugo M
    Clin Microbiol Infect; 2022 Apr; 28(4):614.e5-614.e7. PubMed ID: 34958917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients.
    Fiorino F; Ciabattini A; Sicuranza A; Pastore G; Santoni A; Simoncelli M; Polvere J; Galimberti S; Baratè C; Sammartano V; Montagnani F; Bocchia M; Medaglini D
    Front Immunol; 2022; 13():1017863. PubMed ID: 36248803
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety after the third dose of BNT162b2 anti-SARS-CoV-2 vaccine in patients with solid tumors on active treatment: a prospective cohort study.
    Lasagna A; Bergami F; Lilleri D; Percivalle E; Quaccini M; Alessio N; Comolli G; Sarasini A; Sammartino JC; Ferrari A; Arena F; Secondino S; Cicognini D; Schiavo R; Lo Cascio G; Cavanna L; Baldanti F; Pedrazzoli P; Cassaniti I
    ESMO Open; 2022 Apr; 7(2):100458. PubMed ID: 35427842
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Immune Responses Elicited by SARS-CoV-2 mRNA and Recombinant Protein Vaccine Candidates.
    Wu Y; Zhang H; Meng L; Li F; Yu C
    Front Immunol; 2022; 13():906457. PubMed ID: 35663946
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report.
    Masuda T; Murakami K; Sugiura K; Sakui S; Philip Schuring R; Mori M
    Vaccine; 2022 Mar; 40(13):2044-2052. PubMed ID: 35177302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myopericarditis After the Pfizer Messenger Ribonucleic Acid Coronavirus Disease Vaccine in Adolescents.
    Schauer J; Buddhe S; Colyer J; Sagiv E; Law Y; Mallenahalli Chikkabyrappa S; Portman MA
    J Pediatr; 2021 Nov; 238():317-320. PubMed ID: 34228985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
    Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
    Elife; 2022 Feb; 11():. PubMed ID: 35191378
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.